[ADAP] Adaptimmune Therapeutics plc

Overview

Type of security: Stock

Sector: Health Care

Industry: Biotechnology: Biological Products (No Diagnostic Substances)

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 4.05 Change: 0.06 (1.5%)
Ext. hours: Change: 0 (0%)

chart ADAP

Refresh chart

Strongest Trends Summary For ADAP

ADAP is in the medium-term down -70% below S&P in 1 year.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA ROE ROI
Current Ratio Quick Ratio Long Term Debt/Equity Debt Ratio
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities60.55 M Cash From Investing Activities-17.16 M Cash From Operating Activities-9.73 M Gross Profit
Net Profit-3.12 M Operating Profit-5.16 M Total Assets88.48 M Total Current Assets86.65 M
Total Current Liabilities29.46 M Total Debt Total Liabilities29.46 M Total Revenue2.44 M
Technical Data
High 52 week14.16 Low 52 week3.63 Last close4.12 Last change-3.96%
RSI46.74 Average true range0.37 Beta1.16 Volume75.45 K
Simple moving average 20 days-6.18% Simple moving average 50 days-6.44% Simple moving average 200 days-43.63%
Performance Data
Performance Week-5.94% Performance Month5.91% Performance Quart-18.25% Performance Half-65.23%
Performance Year-66.75% Performance Year-to-date-28.35% Volatility daily5.12% Volatility weekly11.45%
Volatility monthly23.46% Volatility yearly81.27% Relative Volume821.28% Average Volume266.76 K
New High New Low

News

2019-04-18 16:01:10 | Adaptimmune Announces Oral Presentation of Allogeneic SPEAR T-cell Program at 2019 ASGCT Meeting

2019-04-12 15:26:18 | These 3 Falling Knives Are Expected to Outperform

2019-04-02 08:00:00 | Adaptimmune Presents Safety Data with Evidence of Tumor Necrosis in One Patient from ADP-A2AFP Study at American Association for Cancer Research AACR Meeting

2019-04-01 08:00:00 | Adaptimmune Presents Preclinical Data for its Next Generation SPEAR T-cell Targeting MAGE-A4 at the American Association for Cancer Research AACR Annual Meeting

2019-03-15 12:06:00 | Does Adaptimmune Therapeutics plc NASDAQ:ADAP Have A Particularly Volatile Share Price?

2019-02-27 18:39:48 | Edited Transcript of ADAP earnings conference call or presentation 27-Feb-19 1:00pm GMT

2019-02-27 07:29:00 | Adaptimmune Reports Fourth Quarter / Full Year 2018 Financial Results and Business Update

2019-02-07 11:01:23 | Should You Worry About Adaptimmune Therapeutics plc’s NASDAQ:ADAP CEO Salary Level?

2019-02-07 08:00:00 | Adaptimmune to Report Fourth Quarter / Full Year 2018 Financial Results and Business Update on Wednesday, February 27, 2019

2019-01-28 09:38:02 | Adaptimmune Therapeutics PLC ADAP Upgraded to Buy: Here's What You Should Know

2019-01-08 16:30:09 | Radius Exceeds 2018 Financial Guidance, Provides Updates

2019-01-08 09:54:02 | Alnylam ALNY Reports Preliminary Onpattro Revenues for Q4

2019-01-07 07:30:00 | Dose Escalation in Liver Cancer Study with ADP-A2AFP AFP SPEAR T-cells and Moving to Expansion Phase in ADP-A2M10 MAGE-A10 Lung Cancer Study after Favorable Safety Reviews

2019-01-02 10:12:08 | What Percentage Of Adaptimmune Therapeutics plc NASDAQ:ADAP Shares Do Insiders Own?

2018-12-12 08:30:00 | Adaptimmune Announces that Gwen Binder will leave in January 2019

2018-11-28 08:30:00 | Recent Analysis Shows Bellicum Pharmaceuticals, NetEase, Nice, Match Group, SpartanNash, and Adaptimmune Therapeutics Market Influences — Renewed Outlook, Key Drivers of Growth

2018-11-16 11:00:38 | uniQure Stock Rose 35.7% Yesterday—Here’s Why

2018-11-14 11:10:39 | What You Must Know About Adaptimmune Therapeutics plc’s NASDAQ:ADAP Financial Strength

2018-11-07 15:30:33 | Edited Transcript of ADAP earnings conference call or presentation 6-Nov-18 1:00pm GMT

2018-11-06 07:30:00 | Adaptimmune Reports Third Quarter 2018 Financial Results and Business Update

2018-10-25 16:30:00 | Adaptimmune to Report Third Quarter 2018 Financial Results and Business Update on Tuesday, November 6, 2018

2018-10-25 08:53:00 | 3 Beaten-Down Biotech Stocks: Can They Bounce Back?

2018-10-25 07:29:11 | Adaptimmune Therapeutics Worldwide Enters Oversold Territory

2018-10-22 09:48:00 | Adaptimmune's stock tumbles after cancer study results prompts price target cut

2018-10-20 10:45:00 | Updated Data from Ongoing MAGE-A10 and MAGE-A4 Studies Presented at the 2018 ESMO Congress

2018-10-17 07:20:00 | Investor Expectations to Drive Momentum within Arsanis, Dynavax Technologies, Puma Biotechnology, Opko Health, Adaptimmune Therapeutics, and Codexis — Discovering Underlying Factors of Influence

2018-10-08 18:10:00 | Data Updates from Ongoing MAGE-A10 Studies and MAGE-A4 Study to be presented at the European Society for Medical Oncology ESMO 2018 Congress

2018-09-19 07:30:00 | 3 Biotech Stocks That Big Investors Are Snatching Up

2018-09-13 09:19:44 | Should You Be Holding Adaptimmune Therapeutics plc NASDAQ:ADAP Right Now?

2018-09-07 13:14:42 | Adaptimmune Therapeutics plc Announces Closing of Registered Direct Offering of American Depositary Shares

2018-09-05 07:30:00 | Adaptimmune Therapeutics plc Announces Registered Direct Offering of American Depositary Shares

2018-08-27 13:22:25 | Adaptimmune Therapeutics Rose 21% in Week Ended August 24

2018-08-24 10:37:02 | Options Traders Expect Huge Moves in Adaptimmune ADAP Stock

2018-08-20 08:30:00 | Investor Expectations to Drive Momentum within NEXEO SOLUTIONS, Altisource Portfolio Solutions S.A, Celestica, Star Bulk Carriers, Criteo S.A, and Adaptimmune Therapeutics — Discovering Underlying Factors of Influence

2018-08-15 07:30:00 | Third Dosing Cohort to be initiated in MAGE-A4 SPEAR T-cell Basket Study After Favorable Review of Safety from One Billion Cell Dose Cohort

2018-08-03 09:24:56 | Edited Transcript of ADAP earnings conference call or presentation 2-Aug-18 12:00pm GMT

2018-08-02 07:30:00 | Adaptimmune Reports Second Quarter 2018 Financial Results and Business Update

2018-08-02 06:00:00 | Adaptimmune Therapeutics PLC Sponsored ADR to Host Earnings Call

2018-07-26 13:18:33 | Adaptimmune to Report Second Quarter 2018 Financial Results and Business Update on Thursday August 2, 2018

2018-07-24 12:20:17 | Why AdaptImmune collected $27.5M from GSK

2018-07-24 07:30:00 | GSK and Adaptimmune Complete Transition of NY-ESO SPEAR T-cell Therapy Program to GSK

2018-07-18 08:32:42 | Benzinga Pro's 5 Stocks To Watch Today

2018-07-18 07:29:00 | Adaptimmune Announces Favorable Review of Safety from One Billion Cell Dose Cohort in MAGE-A10 SPEAR T-cell Study and Initiation of Third Dosing Cohorts

2018-06-27 10:52:48 | Investors Are Undervaluing Adaptimmune Therapeutics plc NASDAQ:ADAP By 21.72%

2018-06-11 07:30:00 | Study published in Cancer Discovery Indicates that NY-ESO SPEAR T-cells are Long-lived, Self?renewing, and Capable of Persistent Anti-Tumor Effects

2018-06-07 07:45:00 | Complimentary Technical Snapshots on Adverum Biotechnologies and Three More Biotech Stocks

2018-06-04 07:30:00 | Adaptimmune Announces First Patient to Receive One Billion Target Cell Dose after Positive Safety Data from Pilot Study with MAGE-A4 SPEAR T-cells

2018-06-04 07:30:00 | Adaptimmune Presents Detailed Safety Update from Ongoing MAGE-A10 Pilot Studies at ASCO

2018-06-02 08:00:00 | Updated Myxoid/Round Cell Liposarcoma Data with NY-ESO, Presented at ASCO Annual Meeting, Further Supports Promising Benefit: Risk Profile

2018-06-01 07:30:00 | Investor Expectations to Drive Momentum within SK Telecom Co., Adaptimmune Therapeutics, Fiat Chrysler Automobiles N.V, Achillion Pharmaceuticals, Pzena Investment Management, and Sasol — Discovering Underlying Factors of Influence